Insider · CIK 0001863624

Cittadine Andrew

Reports to the SEC for 1 company · WILMETTE, IL

sec.gov

Transactions

Companies

Filings

CIK

0001863624

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-30	MNPRMonopar Therapeutics · Restricted Stock UnitM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−4,384 sh	—	—	35,115
2026-09-30	MNPRMonopar TherapeuticsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+4,384 sh	—	—	59,998
2026-09-30	MNPRMonopar TherapeuticsF Tax Payment	Chief Operating Officer	FTax Payment	−1,944 sh	$79.67	−$155K	58,054
2026-06-30	MNPRMonopar TherapeuticsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+5,254 sh	—	—	57,923
2026-06-30	MNPRMonopar TherapeuticsF Tax Payment	Chief Operating Officer	FTax Payment	−2,309 sh	$92.59	−$214K	55,614
2026-06-30	MNPRMonopar Therapeutics · Restricted Stock UnitM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−5,254 sh	—	—	39,499
2026-03-31	MNPRMonopar TherapeuticsF Tax Payment	Chief Operating Officer	FTax Payment	−1,571 sh	$54.79	−$86.1K	52,669
2026-03-31	MNPRMonopar Therapeutics · Restricted Stock UnitM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−3,514 sh	—	—	44,753
2026-03-31	MNPRMonopar TherapeuticsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+3,514 sh	—	—	54,240
2025-12-31	MNPRMonopar Therapeutics · Restricted Stock UnitM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−4,326 sh	—	—	48,267
2025-12-31	MNPRMonopar TherapeuticsF Tax Payment	Chief Operating Officer	FTax Payment	−1,889 sh	$65.30	−$123K	50,726
2025-12-31	MNPRMonopar TherapeuticsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+4,326 sh	—	—	52,615
2025-12-02	MNPRMonopar Therapeutics · Stock OptionsA Award	Chief Operating Officer	AAward	+8,969 sh	—	—	8,969
2025-12-02	MNPRMonopar Therapeutics · Restricted Stock UnitsA Award	Chief Operating Officer	AAward	+13.9K sh	—	—	52,593
2025-09-30	MNPRMonopar TherapeuticsF Tax Payment	Chief Operating Officer	FTax Payment	−1,896 sh	$81.67	−$155K	48,289
2025-09-30	MNPRMonopar Therapeutics · Restricted Stock UnitsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−4,327 sh	—	—	38,674
2025-09-30	MNPRMonopar TherapeuticsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+4,327 sh	—	—	50,185
2025-06-30	MNPRMonopar Therapeutics · Restricted Stock UnitsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−6,863 sh	—	—	43,001
2025-06-30	MNPRMonopar TherapeuticsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+6,863 sh	—	—	48,848
2025-06-30	MNPRMonopar TherapeuticsF Tax Payment	Chief Operating Officer	FTax Payment	−2,990 sh	$35.78	−$107K	45,858
2025-03-31	MNPRMonopar TherapeuticsF Tax Payment	Chief Operating Officer	FTax Payment	−744 sh	$36.41	−$27.1K	41,985
2025-03-31	MNPRMonopar TherapeuticsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+1,791 sh	—	—	42,729
2025-03-04	MNPRMonopar Therapeutics · Restricted Stock UnitsA Award	Chief Operating Officer	AAward	+40.6K sh	—	—	51,655
2025-03-04	MNPRMonopar Therapeutics · Stock OptionsA Award	Chief Operating Officer	AAward	+43.4K sh	—	—	43,445
2024-12-31	MNPRMonopar TherapeuticsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+1,790 sh	—	—	41,659
2024-12-31	MNPRMonopar Therapeutics · Restricted Stock UnitsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−1,790 sh	—	—	11,074
2024-12-31	MNPRMonopar TherapeuticsF Tax Payment	Chief Operating Officer	FTax Payment	−721 sh	$22.00	−$15.9K	40,938
2024-09-30	MNPRMonopar Therapeutics · Restricted Stock UnitsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−1,791 sh	—	—	12,864
2024-09-30	MNPRMonopar TherapeuticsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+1,791 sh	—	—	40,404
2024-09-30	MNPRMonopar TherapeuticsF Tax Payment	Chief Operating Officer	FTax Payment	−535 sh	$6.74	−$3,605.9	39,869
2024-06-30	MNPRMonopar Therapeutics · Restricted Stock UnitsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−8,952 sh	—	—	73,271
2024-06-30	MNPRMonopar TherapeuticsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+8,952 sh	—	—	195,084
2024-06-30	MNPRMonopar TherapeuticsF Tax Payment	Chief Operating Officer	FTax Payment	−2,019 sh	$0.73	−$1,475.889	193,065
2024-06-20	MNPRMonopar TherapeuticsP Purchase	Chief Operating Officer	PPurchase	+20.5K sh	$0.74	+$15.3K	186,132
2024-06-18	MNPRMonopar TherapeuticsP Purchase	Chief Operating Officer	PPurchase	+12K sh	$0.86	+$10.3K	165,624
2024-06-17	MNPRMonopar TherapeuticsP Purchase	Chief Operating Officer	PPurchase	+12K sh	$0.90	+$10.8K	153,624
2024-06-14	MNPRMonopar TherapeuticsP Purchase	Chief Operating Officer	PPurchase	+12K sh	$0.93	+$11.2K	141,624
2024-06-13	MNPRMonopar TherapeuticsP Purchase	Chief Operating Officer	PPurchase	+12K sh	$0.91	+$10.9K	129,624
2024-06-04	MNPRMonopar TherapeuticsP Purchase	Chief Operating Officer	PPurchase	+12K sh	$0.78	+$9,360	117,624
2024-06-03	MNPRMonopar TherapeuticsP Purchase	Chief Operating Officer	PPurchase	+12K sh	$0.76	+$9,120	105,624
2024-05-31	MNPRMonopar TherapeuticsP Purchase	Chief Operating Officer	PPurchase	+12K sh	$0.64	+$7,731.6	93,624
2024-05-30	MNPRMonopar TherapeuticsP Purchase	Chief Operating Officer	PPurchase	+12K sh	$0.64	+$7,676.4	81,624
2024-05-29	MNPRMonopar TherapeuticsP Purchase	Chief Operating Officer	PPurchase	+12K sh	$0.64	+$7,642.8	69,624
2024-05-22	MNPRMonopar Therapeutics · Stock OptionsA Award	Chief Operating Officer	AAward	+25K sh	—	—	25,000
2024-03-31	MNPRMonopar TherapeuticsF Tax Payment	Chief Operating Officer	FTax Payment	−3,098 sh	$0.68	−$2,109.738	57,624
2024-03-31	MNPRMonopar Therapeutics · Restricted Stock UnitsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−1,791 sh	—	—	49,864
2024-03-31	MNPRMonopar TherapeuticsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+8,952 sh	—	—	60,722
2024-03-31	MNPRMonopar Therapeutics · Restricted Stock UnitsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−8,952 sh	—	—	82,223
2023-12-31	MNPRMonopar TherapeuticsF Tax Payment	Chief Operating Officer	FTax Payment	−3,098 sh	$0.34	−$1,053.94	51,770
2023-12-31	MNPRMonopar TherapeuticsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+8,952 sh	—	—	54,868

Recent filings

Accepted (ET)
Oct 24
Cittadine Andrew0001437749-26-031927
SEC(opens sec.gov)
Jul 24
Cittadine Andrew0001437749-26-022628
SEC(opens sec.gov)
Apr 24
Cittadine Andrew0001437749-26-011078
SEC(opens sec.gov)
Jan 54
Cittadine Andrew0001437749-26-000305
SEC(opens sec.gov)
Dec 84
Cittadine Andrew0001437749-25-037171
SEC(opens sec.gov)
Oct 24
Cittadine Andrew0001437749-25-030285
SEC(opens sec.gov)
Jul 24
Cittadine Andrew0001437749-25-021993
SEC(opens sec.gov)

Companies

Monopar TherapeuticsChief Operating OfficerMNPR

Address

1000 SKOKIE BLVD SUITE 350

WILMETTE, IL, 60091